Jia, J., Niedzwiecki, D., Uronis, H. E., Morse, M., Zafar, Y., Hsu, S. D., … Strickler, J. H. (2018). A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood. In Journal of Clinical Oncology (Vol. 36, pp. 3555–3555). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.3555

Jia, Jingquan, Donna Niedzwiecki, Hope Elizabeth Uronis, Michael Morse, Yousuf Zafar, Shiaowen David Hsu, Emily Bolch, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” In Journal of Clinical Oncology, 36:3555–3555. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3555.

Jia J, Niedzwiecki D, Uronis HE, Morse M, Zafar Y, Hsu SD, et al. A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3555–3555.

Jia, Jingquan, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3555–3555. Crossref, doi:10.1200/jco.2018.36.15_suppl.3555.

Jia J, Niedzwiecki D, Uronis HE, Morse M, Zafar Y, Hsu SD, Bolch E, Nagy RJ, Lanman RB, Talasaz A, Haley S, Nixon AB, Strickler JH. A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3555–3555.